Actuate Therapeutics (ACTU) announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer. The phase 1 portion of the planned Phase 1/2 program aims to determine the maximum tolerated dose or maximum administered dose and dose-limiting toxicities of elraglusib tablets administered once daily and will investigate the pharmacokinetics of elraglusib tablets as well as the preliminary anti-tumor activity of elraglusib when administered as tablets. The goal of the phase 1 portion of the program will be to establish the recommended dose of elraglusib tablets for expansion in subsequent development
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACTU:
- Actuate Therapeutics reports positive Phase 2 pancreatic cancer data
- Actuate Therapeutics says Phase 2 study met primary endpoints
- Actuate announces results from Phase 1 portion of study of elraglusib
- Actuate Therapeutics announces publication of Phase II data for elraglusib
- Actuate Therapeutics Signs $100M Sales Agreement